A near-autonomous AI chemist improves a challenging reaction in medicinal chemistry
OpenAI partnered with Molecule.one to enhance a challenging medicinal chemistry reaction. Their AI, GPT-5.4, connected to Molecule.one
Advanced AI can be a powerful partner for scientists, accelerating discoveries that benefit humanity. OpenAI has demonstrated this in mathematics and theoretical physics, and by lowering the cost of cell-free protein synthesis. This project extends AI's role into medicinal chemistry, where hypotheses must be validated in labs with real molecules and experimental conditions. OpenAI partnered with Molecule.one, integrating GPT-5.4 with Maria, an AI-driven high-throughput laboratory.
The system was tasked with improving a critical reaction class. GPT-5.4 generated research proposals, designed and executed experiments, analyzed data, and suggested follow-up actions. Humans guided the process by setting prompts, grading proposals, and making minor experimental adjustments. They also validated the final results, ensuring a collaborative approach between AI and human expertise.
The most promising proposal, OAI-M1-03, focused on improving the Chan–Lam coupling, a challenging yet vital reaction for forming carbon-nitrogen bonds. GPT-5.4 autonomously identified primary sulfonamides as a high-value substrate class and surprisingly suggested mild oxidants like TEMPO to boost reaction yields. This finding underscores AI's capacity to uncover non-obvious solutions.
Two cycles of experimentation in Maria Lab confirmed significant improvements. Yields increased for 88% of boronic acids and 83% of sulfonamides tested, with the mean yield rising from 16.6% to 25.2%. Human chemists validated these micro-scale results at bench scale, confirming higher yields for most reactions. This reliability is crucial for drug discovery, where reactions must perform consistently in practical lab workflows.
Improvements in Chan–Lam coupling are particularly impactful because synthesis often bottlenecks drug discovery. Sulfonamides, found in many therapeutic areas like anticancer and antimicrobial drugs, historically show low yields in this reaction. Making the Chan–Lam coupling more reliable provides medicinal chemists a practical way to develop and explore new therapeutic molecules. This project exemplifies AI's potential to revolutionize scientific research by acting as a valuable partner throughout the discovery process.
Related articles
The AI world is getting ‘loopy’
AI models are taking a significant leap forward with the adoption of "agentic loops," where AI agents continuously prompt each other to improve code and solve complex problems. This approach, though potentially resource-intensive, promises to unlock new levels of autonomous problem-solving and efficiency in AI applications.
Codex-maxxing for long-running work
Codex is increasingly being used by organizations to support long-running projects that go beyond a single prompt. This whitepaper by Jason Liu offers practical strategies for leveraging Codex as a persistent workspace, managing complex workflows and sustaining progress.
Nobel laureate John Jumper is leaving DeepMind for rival Anthropic
Nobel laureate John Jumper is departing Google DeepMind to join its competitor, Anthropic, after dedicating nearly nine years to DeepMind, where he led the AlphaFold team. Jumper, who shared a Nobel Prize for his work on AlphaFold, expressed gratitude for his time at DeepMind while looking forward to new endeavors.
